Drug Ther Bull. 2017 Jan;55(1):2-5. doi: 10.1136/dtb.2017.1.0451. Epub 2017 Jan 5.
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium, ▼glycopyrronium, tiotropium and ▼umeclidinium, and the long-acting beta agonists (LABAs) indacaterol, ▼olodaterol, and ▼vilanterol (in combination with fluticasone) in the management of COPD. Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Here, we provide a brief overview of the four combinations and consider the place of a LAMA/LABA in people with COPD and any factors that might help to choose between them.
慢性阻塞性肺疾病（COPD）症状的管理通常涉及使用吸入型长效支气管扩张剂。此前，我们已综述了长效毒蕈碱拮抗剂（LAMA）阿地溴铵、格隆溴铵、噻托溴铵和乌美溴铵，以及长效β受体激动剂（LABA）茚达特罗、奥达特罗和维兰特罗（与氟替卡松联合使用）在COPD管理中的应用。目前有四种LAMA与LABA的固定剂量组合，均被指定用于维持性支气管扩张剂治疗，以缓解成年COPD患者的症状。在此，我们简要概述这四种组合，并探讨LAMA/LABA在COPD患者中的地位以及可能有助于在它们之间进行选择的任何因素。
